查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1268929

2023-2030 年全球抗生素市场

Global Antibacterial Drugs Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球抗菌药物市场预计将实现利润丰厚的增长，到 2022 年将达到 438.574 亿美元，到 2030 年将达到 633.268 亿美元。 全球抗菌药物市场预计在预测期内（2023-2030 年）的复合年增长率为 4.8%。 主要的区域参与者正在强调新产品的发布以增加销售额。

例如，2023 年 2 月，日本製药公司 Shionogi 在丹麦推出了一种抗菌药物。 FETCROJA（cefiderocol）在丹麦上市，用于治疗成人（18 岁及以上）需氧革兰氏阴性细菌感染，治疗选择有限。 丹麦的推出是在欧洲迅速扩大头孢地尔可及性的重要一步，在欧洲，抗生素耐药性感染在全球抗菌药物市场上呈上升趋势。

抗菌剂来源于细菌和真菌，通过抑制细胞壁形成、增加细胞膜通透性以及抑制蛋白质合成和核酸代谢等代谢过程发挥作用。 苯氧甲基青霉素和青霉素 V 等抗生素用于治疗与细菌有关的疾病。 但是，它不能治疗感冒、流感和大多数咳嗽等病毒感染。

此外，预计在预测期内，增加抗菌药物临床前开发管道、增加 FDA 批准以及增加主要市场参与者的合作伙伴关係将推动抗菌药物市场的增长。

市场动态

增加研发合作以解决抗菌素耐药性 (AMR) 推动市场增长

根据全球抗生素研究与开发伙伴关係 (GARDP)，当细菌随时间发生变化并且对治疗的反应减弱时，就会产生抗生素耐药性。 每年，数百万人遭受抗生素耐药性之苦，近 130 万人死亡。 此外，世界卫生组织（WHO）已将抗生素耐药性列为全球十大健康威胁之一，是耐药性感染的全球大流行。

2023 年 3 月 9 日，全球抗生素研发伙伴关係 (GARDP) 和利物浦大学签署了一份谅解备忘录，共同合作开展一个新项目，以解决公共卫生领域的抗菌素耐药性 (AMR) 问题。

同样，2023年4月3日，世界卫生组织和GARDP呼吁製造商申请开髮用于治疗多重耐药细菌感染的抗生素“Cefiderocle”。 这是 WHO 药品资格预审计划 (PQP) 首次将多种细菌感染纳入其工作。 PQP 正在发出邀请，以支持使耐多药治疗变得负担得起和可及的举措。

新抗生素开发的挑战阻碍了抗菌市场的增长

发现和创造新的抗生素很困难，因为研发需要时间和成本，而且失败的案例很多。 例如，据说开发新的抗生素需要 10-15 年，耗资超过 10 亿美元。 此外，后期临床试验和首次产品上市后的支出占所有新药研发支出的 80%，阻碍了抗菌药物市场的增长。

COVID-19 影响分析

COVID-19 大流行对抗菌剂市场产生了重大影响。 在医院和诊所，非紧急预约被延迟或推迟，减少了接受适当护理的患者人数。 此外，细菌感染患者可能因害怕感染 COVID-19 而不愿就医。 因此，抗菌药物市场的收入有所下降，但仍用于 COVID，确保了预测期内市场的稳定增长。

俄乌衝突分析

乌克兰的医疗保健系统受到俄罗斯入侵的困扰，俄罗斯入侵摧毁了许多设施，并且由于缺乏熟练的医务人员而可用性有限。 据国家统计，入侵者在乌克兰东部破坏了505家药店，摧毁了其中的47家，干扰了乌克兰政府和其他国家提供的人道主义援助。

此外，在入侵俄罗斯后的 11 天内，药房销售额翻了一番，因为大量慢性病患者购买了这种药物。 抗炎抗风湿药、C09、镇痛药、安定药、降糖药、全身抗生素是最常购买的药物。

从2022年3月开始，乌克兰医药市场销售额出现明显下滑，与2021年同期相比，3月下降11%，4月下降32%，5月和6月下降24%。 下降的原因是移民、就业、医疗人道主义援助和国民收入下降。 1 月份为 31%，2 月份为 45%。

内容

第 1 章研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

  • 按操作类型分类的片段
  • 按药物类型分类的片段
  • 按给药途径分类的片段
  • 药理学片段
  • 按分发渠道分类的摘要
  • 区域摘要

第四章市场动态

  • 影响因素
    • 司机
      • 研发机构加强合作研究以解决抗菌素耐药性 (AMR) 问题可推动市场增长
    • 约束因素
      • 新抗生素开发方面的挑战阻碍了抗菌剂市场的增长
    • 机会
      • 增加临床试验的数量
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 未满足的需求
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • 在 COVID-19 情景之前
    • 当前的 COVID-19 情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 结论

第七章俄乌战争分析

第 8 章按操作类型

  • 抑菌
  • 灭菌

第9章按药物类型分类

  • β-内□胺系统
  • 氨基糖甘类
  • 大环内酯
  • 奎诺酮类
  • 四环素
  • 磺胺
  • 其他

第10章给药途径

  • 口语
  • 肠外
  • 其他

第 11 章药物机制

  • 抑制细胞壁合成
  • 抑制蛋白质合成
  • 细胞膜的变化
  • 核酸合成抑製作用
  • 抗代谢作用

第 12 章分销渠道

  • 零售药房
  • 医院药房
  • 在线药店

第13章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第14章竞争格局

  • 竞争场景
  • 市场份额分析
  • 併购分析

第十五章公司简介

  • 辉瑞公司
    • 公司简介
    • 产品组合和说明
    • 财务摘要
    • 主要发展
  • Sanofi S.A.
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Novartis AG
  • Bristol Myers Squibb Company
  • GlaxoSmithKline Plc
  • Eli Lilly and Company
  • Shionogi & Co., Ltd.

第16章 附录

简介目录
Product Code: PH1511

Market Overview

The global antibacterial drugs market reached US$ 43,857.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 63,326.8 million by 2030. The global antibacterial drugs market is expected to exhibit a CAGR of 4.8% during the forecast period (2023-2030). Major regional players, such as Shionogi & Co., Ltd., Savior Lifetec, Pfizer Inc., and Spero Therapeutics, among others are focusing the new product launches to increase their sales.

For instance, in February 2023, Japanese pharma firm Shionogi launched an anti-bacterial drug in Denmark. FETCROJA (cefiderocol) is now available in Denmark for treating infections due to aerobic Gram-negative bacteria in adults (18 years or older) with limited treatment options. This launch in Denmark is an important step in rapidly expanding access to cefiderocol across Europe, where we see an increasing trend in the number of antibiotic-resistant infections enhancing the global antibacterial drugs market.

Antibacterial drugs are derived from bacteria or molds and work by inhibiting cell wall production, increasing cell membrane permeability, and interfering with protein synthesis, nucleic acid metabolism, and other metabolic processes. Antibacterial drugs, which include phenoxymethylpenicillin and penicillin V, are used to treat bacteria-related disorders. However, it doesn't treat viral infections such as colds, flu, and most coughs.

Furthermore, rising preclinical development pipelines in antibacterial agents, increasing FDA approvals, and increasing partnerships by key market players are the factors that are expected to drive the antibacterial drugs market growth over the forecast period.

Market Dynamics

The increasing collaborations by R&D organizations to address antimicrobial resistance (AMR) drives market growth

According to the Global Antibiotic Research and Development Partnership (GARDP), antibiotic resistance develops when bacteria change over time and no longer respond to treatment. Every year, millions of people suffer from antibiotic resistance, and almost 1.3 million people die. Moreover, the World Health Organisation has identified antibiotic resistance as one of the top ten global health threats and it is spreading globally as a pandemic of drug-resistant infections.

On March 9, 2023, the Global Antibiotic Research and Development Partnership (GARDP) and the University of Liverpool signed a Memorandum of Understanding (MOU) to collaborate on new projects to address antimicrobial resistance (AMR) for the benefit of public health.

Similarly, on April 3, 2023, the World Health Organization and GARDP invited manufacturers to apply to develop cefiderocol, an antibiotic used to treat multidrug-resistant bacterial infections. This is the first time the WHO Prequalification of Medicines Programme (PQP) has included multiple bacterial infections in its work. The PQP has extended an invitation to help initiatives promote the affordability and availability of multidrug-resistant bacteria therapy.

Challenges in developing new antibiotics are hampering the growth of the antibacterial drugs market

Discovering and creating new antibiotics is difficult since the research and development process is time-consuming, costly, and frequently fails. For instance, a new antibiotic can take 10-15 years and more than $1 billion to be developed. Moreover, the final phase of trials and after an initial product launch can account for 80% of the total R&D spend on a new drug, thereby inhibiting the antibacterial drug market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the antibacterial drug market. Hospitals and clinics have delayed or postponed non-emergency appointments, leading to fewer patients receiving proper treatment. Additionally, patients with bacterial infections may have been reluctant to seek medical attention due to fears of contracting COVID-19. As a result, revenue in the antibacterial drugs market has decreased, but they are still used for COVID, ensuring the market's steady growth during the forecast period.

Russia-Ukraine Conflict Analysis

The Ukrainian healthcare system is facing issues due to the Russian invasion, with many facilities destroyed and limited availability due to a shortage of skilled medical staff. According to the national statistics, the invaders have damaged 505 pharmacies in Eastern Ukraine, 47 of which were destroyed, and are blocking humanitarian aid provided by the Ukrainian government or other countries.

Besides, the volume of pharmacy sales doubled in the first 11 days of the Russian invasion due to large amounts of medications purchased by patients with chronic conditions. The top most often bought medicines were antiinflammatory and antirheumatic products, C09, analgesics, psychoanaleptics, diabetes drugs, and antibacterials for systemic use.

The Ukrainian pharmaceutical market has seen a significant drop in sales since March 2022, with 11% in March, 32% in April, and 24% in May and June compared to the same period of 2021. The decline is due to migration, occupation, medical humanitarian aid, and a drop in the income of the population. The downward trend began just after a substantial growth of the market before the war, with 31% in January and 45% in February.

Segment Analysis

The global antibacterial drugs market is segmented based on the action type, drug type, route of administration, drug mechanism, distribution channel, and region.

The oral segment is expected to hold a dominant position in the market over the forecast period.

The oral segment accounted for the highest market stake accounting for approximately 48.8% of the antibacterial drugs market in 2022. Oral administration is the most practical and economical way to administer antibiotics, but it can be unpredictable in certain people. Oral therapy is used when it is tolerable and provides a sufficient therapeutic effect, while parenteral therapy is reserved for patients with difficulty having oral medicines or needing higher antimicrobial activity.

Moreover, oral administration over intravenous administration is beneficial due to the absence of thrombophlebitis and cannula-related infections, reduced drug costs, and decreased hidden costs. It can also make early hospital discharge or discharge straight from the emergency room possible.

For instance, oral antibiotics can treat uncomplicated UTIs, but readmission rates should not be lower than intravenous antibiotics. The bioavailability of oral antibiotics is an important factor in determining the effectiveness of intravenous drugs, as they may be substituted depending on the condition and drug penetration. Antibiotics such as Clindamycin, Fluconazole, Metronidazole, Sulfamethoxazole/trimethoprim, and Doxycline are commonly administered orally. Therefore, this segment will boost the global antibacterial drugs market growth over the forecast period.

Geographical Analysis

The merger and acquisition strategy by the key market players is to dominate the North American region.

North America is expected to dominate the worldwide antibacterial drugs market, accounting for around 1/3rd of this market, with the U.S. being the major contributor. For instance, in May 2022, Entasis Therapeutics, an antibiotic biotech, was acquired by Innoviva. On a fully diluted basis, the transaction values Entasis' stock at $113 million. Entasis' flagship medicine, SUL-DUR, outperformed an existing treatment in phase 3 clinical trial last year and is scheduled for FDA approval in mid-2022. SUL-DUR is a targeted antibiotic.

Competitive Landscape

The major global players in the market include: Pfizer Inc., Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Shionogi & Co., Ltd., Eli Lilly and Company, GlaxoSmithKline Plc, Bristol Myers Squibb Company, and Novartis AG, among others.

Why Purchase the Report?

  • To visualize the global antibacterial drugs market segmentation based on the action type, drug type, route of administration, drug mechanism, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of antibacterial drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global antibacterial drugs market report would provide approximately 77 tables, 76 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Action Type
  • 3.2. Snippet by Drug Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Drug Mechanism
  • 3.5. Snippet by Distribution Channel
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing collaborations by R&D organizations to address antimicrobial resistance (AMR) drives market growth
    • 4.1.2. Restraints
      • 4.1.2.1. Challenges in developing new antibiotics are hampering the growth of the antibacterial drugs market
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing number of clinical trials
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Action Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
    • 8.1.2. Market Attractiveness Index, By Action Type
  • 8.2. Bacteriostatic*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Bactericidal

9. By Drug Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.1.2. Market Attractiveness Index, By Drug Type
  • 9.2. Beta-lactams*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Aminoglycosides
  • 9.4. Macrolides
  • 9.5. Quinolones
  • 9.6. Tetracyclines
  • 9.7. Sulfonamide
  • 9.8. Others

10. By Route of Administration

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.1.2. Market Attractiveness Index, By Route of Administration
  • 10.2. Oral*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Parenteral
  • 10.4. Others

11. By Drug Mechanism

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
    • 11.1.2. Market Attractiveness Index, By Drug Mechanism
  • 11.2. Inhibition of Cell Wall Synthesis*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Inhibition of Protein Synthesis
  • 11.4. Alteration of Cell Membranes
  • 11.5. Inhibition of Nucleic Acid Synthesis
  • 11.6. Antimetabolite Activity

12. By Distribution Channel

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.1.2. Market Attractiveness Index, By End User
  • 12.2. Retail Pharmacies*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Hospital Pharmacies
  • 12.4. Online Pharmacies

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
    • 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.8.1. The U.S.
      • 13.2.8.2. Canada
      • 13.2.8.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
    • 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.8.1. Germany
      • 13.3.8.2. The U.K.
      • 13.3.8.3. France
      • 13.3.8.4. Italy
      • 13.3.8.5. Spain
      • 13.3.8.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
    • 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.8.1. Brazil
      • 13.4.8.2. Argentina
      • 13.4.8.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
    • 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.8.1. China
      • 13.5.8.2. India
      • 13.5.8.3. Japan
      • 13.5.8.4. Australia
      • 13.5.8.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Action Type
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Mechanism
    • 13.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Company Profiles

  • 15.1. Pfizer Inc.*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. Sanofi S.A.
  • 15.3. Bayer AG
  • 15.4. Teva Pharmaceutical Industries Ltd.
  • 15.5. Dr. Reddy's Laboratories Ltd.
  • 15.6. Novartis AG
  • 15.7. Bristol Myers Squibb Company
  • 15.8. GlaxoSmithKline Plc
  • 15.9. Eli Lilly and Company
  • 15.10. Shionogi & Co., Ltd.

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us